Immunic’s (IMUX) Buy Rating Reiterated at B. Riley

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reiterated by investment analysts at B. Riley in a note issued to investors on Wednesday,Benzinga reports. They presently have a $6.00 price target on the stock.

A number of other research firms also recently commented on IMUX. William Blair began coverage on shares of Immunic in a research report on Tuesday, March 25th. They issued an “outperform” rating on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Thursday, April 10th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Tuesday. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Immunic currently has a consensus rating of “Buy” and a consensus target price of $13.20.

Immunic Stock Up 4.0 %

Shares of IMUX opened at $0.98 on Wednesday. The company has a market capitalization of $88.35 million, a price-to-earnings ratio of -0.80 and a beta of 1.91. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11. The stock has a 50 day moving average price of $1.08 and a 200 day moving average price of $1.15.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC increased its position in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after acquiring an additional 479,846 shares during the period. Renaissance Technologies LLC lifted its position in Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after acquiring an additional 177,542 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock valued at $205,000 after purchasing an additional 96,894 shares during the last quarter. Barclays PLC acquired a new position in shares of Immunic in the fourth quarter valued at approximately $84,000. Finally, HB Wealth Management LLC purchased a new stake in shares of Immunic during the fourth quarter worth approximately $81,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.